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Abstract
In tropical regions millions of people still live at risk of malaria infection. Indeed the emergence of resistance to chloroquine
and other drugs in use in these areas reinforces the need to implement alternative prophylactic strategies. Genistein is a
naturally occurring compound that is widely used as a food supplment and is thought to be effective in countering several
pathologies. Results presented here show that genistein inhibits liver infection by the Plasmodium parasite, the causative
agent of malaria. In vitro, genistein decreased the infection rates of both mouse and human hepatoma cells by inhibiting the
early stages of the parasite’s intracellular development. Oral or intraperitoneal administration of genistein decreased the
liver parasite load of P. berghei-infected mice. Moreover, mice fed on a genistein-supplemented diet showed a significant
reduction in Plasmodium liver infection as well as a reduced blood parasitemia and partial protection from severe disease.
Since genistein is a safe, low-cost, natural compound that can be used permanently in a diet, we propose its use as a
prophylactic agent against malaria for endemic populations and long-time travelers.
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Introduction
In recent years, Plasmodium falciparum, the most virulent malaria
parasite species that infects humans, has developed increasing
resistance to anti-malarial drugs in use. The development of new
drugs has been slow and insufficient to overcome the problem of
drug resistance. Moreover, the most affected populations in
developing countries cannot afford most available therapies. In
this context, not only toxicity but also cost effectiveness and
distribution are important factors that need to be considered when
developing novel intervention approaches against malaria.
The hepatic stage is the first step of any natural malaria
infection and a prerequisite for the subsequent blood stage, when
disease-associated pathology occurs. The obligatory, yet silent,
nature of liver stage infection makes it an attractive target for
prophylactic anti-malarial intervention strategies [1]. Moreover, a
decrease of the parasite load in the liver has been shown to be
associated with a decrease in the severity of the disease [2,3].
Clinical manifestations of malaria cover a wide range of
symptoms. Although most infected individuals will only have a
relatively benign febrile illness, 1–3 million deaths per year occur
from severe malaria, which includes several syndromes such as
severe anaemia, acute respiratory distress or cerebral malaria.
Genistein, a major component of soybeans, is a broad tyrosine
kinase inhibitor [4] and has been ingested by several Asian
populations for centuries without any obvious adverse effects.
Several clinical trials have successfully addressed the usefulness of
genistein as a prophylactic agent for certain types of cancer and
chronic diseases [5]. Moreover, genistein has been shown to
inhibit in vitro the intraerythrocytic development of P. falciparum
and P. chabaudi, an effect that has been attributed to its action as a
tyrosine kinase inhibitor [6–8]. We have previously shown that, in
the liver, signaling through the host tyrosine kinase receptor MET
facilitates sporozoite infection [9]. Thus, we hypothesized that
genistein might influence hepatic infection by Plasmodium and
sought to investigate its potential as a prophylactic anti-malarial.
Here, we demonstrate that genistein affects P. berghei ANKA
sporozoite development within hepatocytes and thereby reduces
hepatic infection both in vitro and in vivo. Importantly, we show that
genistein given as a food supplement to mice affects the full course
of a malaria infection, including the development of pathology, by
reducing the extent of liver infection by Plasmodium.
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Genistein Inhibits in vitro Hepatocyte Infection by P.
berghei ANKA Sporozoites
To determine whether genistein has any effect on the hepatic
infection by Plasmodium sporozoites, cultures of Hepa1-6 cells, a
mouse hepatoma cell line, were infected with P. berghei ANKA
sporozoites in the presence of different doses of genistein. Twenty-
four hours after sporozoite addition, the number of infected cells
was determined by counting the total number of intracellular
developing parasites (exo-erythrocytic forms, EEFs). The results
show that genistein significantly inhibits Hepa1-6 cell infection in a
dose-dependent manner (p,0.05) (Figure 1A). We also observed
that genistein decreases infection by Plasmodium sporozoites in 2
different human hepatoma cell lines, HepG2 or Huh7 cells
(7468% and 6864% reduction in infection, respectively;
p,0.01), to a similar extent as that observed in the murine cell
line (Figure 1B, C). Genistein treatment does not lead to any signs
of loss of cell viability or reduced proliferation. Indeed, HepG2 or
Huh7 cells treated with genistein show constant number of cells as
well as constant proportion of cell death (Figure 1D, E). Taxol
treated Huh7 cells were used as positive control. To test the
possibility that genistein has a direct effect on Plasmodium
sporozoites, preventing them from invading the cells, P. berghei
ANKA sporozoites were incubated with 100 mM genistein for
30 min and, after several washes to remove genistein, added to
HepG2 cells. EEF number was assessed 24 hours later and no
significant difference was observed between the infection levels of
cells infected with sporozoites pre-treated with genistein and those
infected with vehicle-treated sporozoites (Figure 1F). Interestingly,
pre-treatment of cells for 2 h prior to sporozoite addition led to a
small but significant reduction of infection, which again strongly
suggests the effect of genistein in infection is due to an effect on the
host cell and not on the parasite (p,0.05) (Figure 2G). Altogether
the data shows that genistein strongly affects host cell infection by
P. berghei ANKA without having a direct action on sporozoites.
Genistein Impairs Early Plasmodium Sporozoite
Development Inside Host Cells
After invasion of a hepatocyte, each parasite replicates to
thousands of merozoites that are subsequently released into the
blood stream. As parasites develop and replicate inside hepato-
cytes, the size of EEFs increases. We noticed a striking difference
between the sizes of EEFs in control versus genistein-treated cells
(Figure 2A). The quantification of EEF areas in both groups of
cells showed that EEFs are significantly smaller in genistein-treated
cells than in untreated controls (Figure 2B), suggesting that
genistein affects the development of Plasmodium sporozoites inside
host cells.
Hepatocyte infection by Plasmodium may be divided into three
consecutive steps: cell traversal, productive hepatocyte invasion
and intracellular development. In our in vitro infection model, over
95% of the infective sporozoites have completed the migration and
invasion steps at 2 hours after addition to the cells [10]. Later,
after 6 hours, sporozoites have changed their morphology and
have acquired a round form and after 12 hours their size has
started to increase. In order to identify the time-scale of genistein
action, the drug was added to HepG2 cell cultures at different
times after addition of P. berghei ANKA sporozoites. Genistein
significantly reduced infection to approximately the same extent
regardless of whether it was added to the cells prior to infection or
up to 6 hours after sporozoite addition (p,0.05) (Figure 2C). This
finding suggests that genistein reduces infection not by interfering
with sporozoite invasion but rather by interfering with the
Figure 1. Genistein inhibits in vitro hepatoma cell infection by
Plasmodium sporozoites. Cultured Hepa1-6 cells were incubated with
increasing doses of genistein (A) and cultured HepG2 and Huh7 cells
were incubated with 25 mM of genistein (B) and (C). As control, cells
were treated with equivalent volumes of DMSO as in the genistein
treated groups. The number of infected cells was determined 24 hours
after infection with 4610
4 P. berghei ANKA sporozoites and is shown as
the total number of EEFs in each coverslip. Each condition was assayed
in duplicate in (A) or triplicate in (B) and (C). w p,0.05, ww p,0.01
(TTest relative to control group). Bar plot shows one representative of 3
independent experiments, error bars represent s.d. of mean number of
EEFs in each condition. (D) Cultured HepG2 cells were incubated with
different concentrations of genistein, or DMSO (control). After 24 hours
the number of adherent cells in 10 microscope fields representing
approximately 20% of the total area was assessed at 4006magnifica-
tion. Each condition was assayed in duplicate. (E) Cultured Huh7 were
incubated with Genstein or Taxol, along with their respective controls
of DMSO, and allowed to grow for 24 hours. After this time both
adherent and non-adherent cells were collected and incubated with
propidium iodide. Percentage of death cells was quantified by flow
cytometry. Bar plot shows one representative of 3 independent
experiments, error bars represent s.d. of mean cell death percentage
in each condition (n=3). ww p,0.01 (TTest relative to control group).
(F) P. berghei ANKA sporozoites were incubated with 100 mM genistein
or DMSO for 30 min. Sporozoites were washed with PBS to remove
genistein and used to infect cultured HepG2 cells. Infection was
determined 24 hours post-infection by counting the total number of
EEFs in each coverslip. Each experimental condition was assayed in
triplicate. Bar plot shows one representative of 3 independent
experiments. Error bars represent s.d. of mean number of EEFs in each
condition (n=3). (G) Huh7 cells were incubated with 25 mM genistein or
DMSO for 2 h. Cells were then washed with PBS and fresh medium to
remove genistein. P. berghei sporozoites were then added to these
cells. Infection was determined 24 hours post-infection by counting the
total number of EEFs in each coverslip. Each experimental condition
was assayed in triplicate. Bar plot shows one representative of 3
independent experiments. Error bars represent s.d. of mean number of
EEFs in each condition (n=3).
doi:10.1371/journal.pone.0002732.g001
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was progressively lost when it was added at later time-points
(Figure 2C). Still with the objective of finding genistein’s time of
action we added the drug to HepG2 cell cultures immediately
prior to addition of P. berghei ANKA sporozoites, and then
removed it at different times after infection (Figure 2D). Genistein
reduced infection when it was present during the first 4 hours of
infection. The degree of inhibition increases with exposure time
Figure 2. Genistein suppresses the early development of parasites within hepatocytes. (A) Hepa1-6 cells were incubated with genistein or
DMSO and inoculated with 4610
4 P. berghei ANKA sporozoites. The two images show EEFs observed 24 hours after infection of control (left) or
genistein-treated cells (right) at a 10006 magnification. Bar=2.5 mm. (B) Distribution of EEFs according to size. Hepa1-6 cells were treated with
genistein or DMSO (control) immediately prior to inoculation with 4610
4 P. berghei ANKA sporozoites and the size of 100 EEFs from different
coverslips was determined 24 hours later. The figure shows the frequency of EEFs with sizes between 0 and 40 mm
2. # control; N 25 mM genistein.
P=5.9610
225 (TTest relative to the control group). The results are representative of 3 independent experiments. (C) Incubation of cultured HepG2
cells with 25 mM genistein or DMSO (control) at various times after addition of 4610
4 P. berghei ANKA sporozoites. Infection was determined 24 hours
after sporozoite addition by counting the total number of EEFs per coverslip. The results are expressed as the percentage of EEFs relative to the
average number of EEFs in the control samples, taken as 100%. (D) Incubation of cultured HepG2 cells with 25 mM genistein or DMSO (control) at the
time of addition of 4610
4 P. berghei ANKA sporozoites and washed at various time-points. Infection was determined 24 hours after sporozoite
addition by counting the total number of EEFs per coverslip. The results are expressed as the percentage of EEFs relative to the average number of
EEFs in the control samples, taken as 100%. w p,0.05, ww p,0.01 www p,0.001 (TTest relative to control group). Bar plots show one
representative of 3 independent experiments, error bars represent s.d. of mean number of EEFs in each condition (n=3). (E) Flow cytometry analysis
of the invasion rate in genistein-treated and control Huh7 cells at 2 hours after addition of 3610
4 PbGFP sporozoites. Bar plots show one
representative of 3 independent experiments, error bars represent s.d. of mean percentage of GFP positive cells in each condition (n=3). (F) Flow
cytometry analysis of genistein-treated and control Huh7 cells at 6, 30 and 44 hours after addition of 3610
4 PbGFP sporozoites, and of primaquine-
treated and control cells at 44 hours after adition of 3610
4 PbGFP sporozoites. Red line represents Genistein treated cells and black line represents
control cells. The graphs show one representative dataset of triplicate samples. (G) Quantification of the GFP intensity of PbGFP-infected genistein-
treated (red bars) and non-treated (black bars) cells at the same time points as in E. ww p,0.01 (TTest relative to control group). Bar plots show one
representative of 3 independent experiments, error bars represent s.d. of mean GFP intensity in each condition (n=3).
doi:10.1371/journal.pone.0002732.g002
Prophylactic Strategy
PLoS ONE | www.plosone.org 3 July 2008 | Volume 3 | Issue 7 | e2732and is most significant when the drug is present during the whole
course of infection (p,0.001) (Figure 2D).
To further examine the effect of genistein in the development of
sporozoites inside host cells, we used a recently described Flow
Activated Cell Sorting (FACS) method [10] where we showed that
EEFs of P. berghei ANKA expressing GFP show GFP intensity
proportional to the EEF developmental stage. Having shown that
genistein-treated cells and their controls were equally invaded by P.
berghei ANKA expressing GFP sporozoites at 2 hours post–infection
(Figure 2E), genistein-treated cells were collected and analyzed by
flow cytometry at 6, 30 and 44 hours, after addition of P. berghei
ANKA expressing GFP sporozoites. Solvent-treated cells infected
with P. berghei ANKA expressing GFP sporozoites, collected and
analyzed at the same times, wereused as negative controls. Whereas
the GFP intensity of infected and solvent-treated cells increases
significantly with time as a result of the parasites’ intra-cellular
development, the increase in GFP intensity of genistein-treated cells
is significantly less pronounced (Figure 2F). The quantification of
the GFP intensity of triplicate samples of genistein-treated and
control cells at each of the time-points analyzed shows that in the
first hours after infection both sets of samples show similar GFP
intensities, and the difference between these intensities then
increases with time (p,0.01) (Figure 2G). These results provide
evidencethatgenisteinactssubsequent tocellinvasion,byinhibiting
the parasites’ early development inside host cells.
The concentration of genistein required to inhibit infection by
50% (IC50) was determined for P. berghei ANKA infection of Huh7
cells (p,0.05) (Figure 3A), and for P. yoelii infection in Hepa1-6
cells (p,0.05) (Figure 3B). Plasmodium infection of cells treated with
increasing amounts of genistein was measured by quantitative real-
time PCR (qRT-PCR), as this method takes into account both the
number and the development of EEFs, since both contribute to the
total number of parasite copies detected. Genistein inhibited
infection with an IC50 of ,20 and ,30 mM for P. berghei and P.
yoelii infections, respectively. This was performed in parallel to
experiments where primaquine was tested in P. berghei infection of
Huh7 cells. The IC50 value obtained for primaquine in those
conditions was 13 mM (with an R
2 value of 0.9658). In addition to
hepatoma cell lines primary mouse hepatocyte cultures were also
used. As observed in the cell lines, genistein reduced the infection
of these cells by P. berghei sporozoites (data not shown). Our
findings demonstrate that genistein impairs the developmental/
replication of the parasite in cultured hepatocytes without affecting
the viability of the host cells.
Genistein Decreases in vivo Mouse Liver Infection by P.
berghei ANKA Sporozoites
To investigate the in vivo relevance of our findings with cultured
hepatocytes we treated mice with genistein by intraperitoneal (i.p.)
administration immediately prior to the intravenous (i.v.) inocula-
tion of Plasmodium sporozoites. Solvent-treated mice were used as
controls. Quantification of parasite load in the livers 40 hours after
P. berghei or P. yoelii sporozoite injection showed that a single i.p.
administration of genistein at a dose of 200 mg/kg reduced
infection (p,0.05) (Figure 4A, B). We then tested the effect of oral
administration of a genisteinsuspensionin waterto micepriorto i.v.
injection of P. berghei ANKA sporozoites. Water was administered to
control mice. Administration of a single 200 mg/kg dose of
genistein 6 hours prior to sporozoite inoculation, aiming to increase
genistein levels in the liver at the time of sporozoite development,
resulted in a 64% reduction of liver infection of genistein-treated
mice relative to their control counterparts, measured 40 hours after
infection (p,0.05) (Figure 4C).
The above findings constitute a proof-of-principle that genistein
administered orally may be useful for malaria prophylaxis.
However, prophylactic interventions based on daily drug adminis-
tration are difficult to implement in developing countries, in
particular if the whole population requires treatment. Thus, we
sought to test the effect of genistein administration through diet.
Mice were kept on a 1000 ppm genistein-supplemented diet since
weaning (see methods for details), while control mice were kept on
exactly the same diet but without genistein supplementation. Seven
to 10 weeks old mice were inoculated i.v. with P. berghei ANKA
sporozoites and liver infection was determined 40 hours after
sporozoite injection. The liver parasite load was significantly
Figure 3. Genistein’s 50% Inhibitory Concentration (IC50). (A)
Cultured Huh7 cells were treated with increasing doses of genistein or
DMSO (control), and inoculated with 4610
4 P. berghei ANKA
sporozoites. Infection was determined 24 hours later by parasite-
specific 18S rRNA qRT PCR, and an IC50 of 20 mM was calculated for
genistein’s inhibition of infection. Black circles represent the mean of P.
berghei ANKA18S rRNA expression in each condition (n=3). (B) Cultured
Hepa1-6 cells were treated with increasing doses of genistein or DMSO
(control), and inoculated with 3.5610
4 P. yoelii sporozoites. Infection
was determined 24 hours later by parasite-specific 18S rRNA qRT PCR,
and an IC50 of 30 mM was calculated for genistein’s inhibition of
infection. Black circles represent the mean of P. berghei ANKA18S rRNA
expression in each condition (n=3).
doi:10.1371/journal.pone.0002732.g003
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the untreated controls (p,0.001) (Figure 4, D and E). This effect
was even more pronounced on the progeny of couples kept on this
genistein-supplemented diet, presumably because those litters were
exposed to genistein supplementation since breastfeeding. More-
over, the degree of infection was inverselycorrelatedto the genistein
levels in the sera of the mice (Figure 4F). These results show that the
genistein levels achieved by a genistein-supplemented diet are
sufficient to decrease the infection of the liver with Plasmodium.
Genistein Decreases Disease Severity Through an Effect
on Liver Stage Infection
By reducing liver infection and, consequently, the number of
merozoites that are generated in the liver, genistein treatment is
likely to reduce the parasite burden in the blood. Thus, we
determined whether the genistein diet had an impact on the blood
stage of infection, which is responsible for disease symptoms. Mice
kept on a genistein diet and controls were inoculated i.v. with P.
berghei ANKA sporozoites and infection was allowed to proceed to
Figure 4. Genistein decreases mouse liver lnfection by P. berghei ANKA sporozoites. (A) Mice treated by intraperitoneal injection of 4 mg
of genistein in a volume of 200mL DMSO, or with DMSO alone (control), were injected intravenously with P. berghei ANKA sporozoites (1610
4/mouse).
Infection was determined 40 hours later by parasite-specific 18S rRNA qRT PCR (n=4 mice per group). w p,0.05 (TTest relative to control group). Bar
plots show one representative of 3 independent experiments. Error bars represent s.d. of mean P. berghei ANKA 18S rRNA expression in each
condition (n=3). (B) Mice treated by intraperitoneal injection of 4 mg of genistein in a volume of 200mL DMSO, or with DMSO alone (control), were
injected intravenously with P. yoelii ANKA sporozoites (1610
4/mouse). Infection was determined 40 hours later by parasite-specific 18S rRNA qRT PCR
(n=4 mice per group). w p,0.05 (TTest relative to control group). Bar plots show one representative of 3 independent experiments. Error bars
represent s.d. of mean P. yoelii ANKA 18S rRNA expression in each condition (n=3). (C) Mice treatment by oral administration of 4 mg of genistein
suspended in 200 mL water or with the same volume of water alone (control), 6 hours prior to intravenous injection of sporozoites (1610
4/mouse).
Infection was determined 40 hours later by parasite-specific 18S rRNA qRT-PCR. n=3 mice per group. w p,0.05 (TTest relative to control group). Bar
plots show one representative of 3 independent experiments. Error bars represent s.d. of mean P. berghei ANKA 18S rRNA expression in each
condition (n=3). (D) Mice kept on a genistein-supplemented diet since breastfeeding or with the same diet without supplementation as a control,
were injected intravenously with P. berghei ANKA sporozoites (1610
4/mouse). Infection was determined 40 hours later by parasite-specific 18S rRNA
qRT-PCR. n=14 control group; n=17 genistein treated group. ¤ individual mouse, red bar represents the group average. P=0.00007 (TTest relative
to control group). Results are representative of 3 independent experiments. (E) Compiled data of liver infection from 5 independent experiments with
mice fed on genistein-supplemented diet for a minimum of 5 weeks and injected intravenously with P. berghei ANKA sporozoites (1610
4/mouse).
Infection was determined 40 hours later by parasite-specific 18S rRNA qRT-PCR. Results are expressed as frequency of mice that present a certain
level of infection. Infection is expressed as the percentage of parasite specific 18S rRNA taking the average control (non-supplemented diet) as 100%.
e control diet (n=60), ¤ 1000 ppm genistein-supplemented diet (n=69). P=5.8610
25 (Wilcoxon rank sum test to control group). (F) Inverse
correlation between genistein levels in the sera and Plasmodium infection in the liver. Mice kept under genistein-supplemented diet since
breastfeeding or with the same diet without supplementation, used as controls, were injected intravenously with P. berghei ANKA sporozoites
(1610
4/mouse). Infection was determined 40 hours later by parasite-specific 18S rRNA qRT-PCR, sera were collected and genistein levels were
determined for individual mice. Total genistein levels (ng/mL) in the sera are plotted against liver infection of individual mice. Infection is expressed
as the percentage of parasite specific 18S rRNA taking the average control (non-supplemented diet) as 100%. ¤ represent the coordinates for
genistein level (yy) and infection (xx) for individual mice. The red line represents the inverse correlation between the two parameters measured.
doi:10.1371/journal.pone.0002732.g004
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in peripheral blood) was determined at regular time intervals. In
genistein-fed mice the appearance of blood parasitemia was
significantly reduced as compared to controls (p,0.01 for each
day) (Figure 5A) and the percentage of parasitized red cells,
remained lower throughout the entire course of the infection
(Figure 5B). C57BL/6 mice infected with P. berghei ANKA die
within 6–12 days due to the development of a complex neurological
syndrome consisting of hemi- or paraplegia, head deviation,
tendency to roll–over on stimulation, ataxia and convulsions. Given
its similarities to human CM, this neurological syndrome is referred
to as experimental cerebral malaria (ECM). This model has been
used forsometime byseveraldifferentgroupsaroundtheworld.We
have previously used this model and have observed that the mice
present blood-brain-barrier disruption as soon as symptoms arise
[11]. Importantly, more than half of the mice fed on the genistein-
supplemented diet were protected from developing ECM. At
25 days after infection, the survival of mice fed on the genistein-
supplemented diet and that of mice fed on a control diet without
genistein supplementation was 56% and 18%, respectively
(p,0.001) (Figure 5C). The reduction in blood infection could be
due to the observed effect on liver infection but also to a direct effect
of genistein on the blood stages. To test the latter possibility, mice
fed on a genistein-supplemented diet were infected with P. berghei
ANKA-infected red blood cells (iRBC) and their parasitemias were
compared to those of untreated, infected mice. There was no
significant difference between the development of parasitemia in
both groups of mice (Figure 5D). These results show that, by
affecting the liver stage of infection, genistein reduces the parasite
load in the blood and the severity of the disease.
Figure 5. Genistein partially protects from cerebral malaria. (A) Mice fed on a genistein-supplemented or control diet since breastfeeding
were injected intravenously with P. berghei ANKA sporozoites (1610
4/mouse) and maintained for the analysis of blood infection. Peripheral blood
parasitemia was determined, at different time points after infection, by counting the number of infected red blood cells in Giemsa stained thin blood
films. ¤ control diet; e 1000 ppm genistein-supplemented diet, n=3mice per group. w p,0.005 (TTest relative to control group). The results are
representative of 3 independent experiments with a total of 15 control mice and 19 genistein-treated mice. (B) Same as in A between day 2 and day 8
after intravenous injection of P. berghei ANKA sporozoites by counting the number of infected red blood cells in Giemsa stained thin blood films. ¤
control diet; e 1000ppm genistein-supplemented diet, n=3 mice per group. (C) Cumulative survival of mice fed on a genistein-supplemented or
control diet since breastfeeding when injected intravenously with P. berghei ANKA sporozoites (1610
4/mouse). Fifty-six percent of the mice fed on
the genistein-supplementd diet and infected with P. berghei ANKA sporozoites are protected from developing cerebral malaria when compared with
twenty percent of mice fed on the control diet. ¤ control diet, n=15; e 1000 ppm genistein supplemented diet, n=16. The gray area represents the
time window for developing cerebral malaria in this model. P=0.067 (Log-Rank Test). (D) Mice fed on a genistein-supplemented or control diet since
breastfeeding were infected by intraperitoneal injection of 1610
6 P. berghei ANKA iRBC. Peripheral blood parasitemia was determined throughout
infection by counting the number of infected red blood cells in Giemsa stained thin blood films. Parasitemia indicates the percentage of iRBC in a
given number of total red blood cells. ¤ control diet, n=6; e 1000 ppm genistein-supplemented diet, n=7. Results are representative of 2
independent experiments with a total of 11 control mice and 12 genistein-treated mice.
doi:10.1371/journal.pone.0002732.g005
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Phosphorylation
The rationale to test the effect of genistein, a tyrosine kinase
inhibitor, in infection was that signaling trough the tyrosine kinase
receptor Met might favor parasite development in hepatocytes. To
determine whether genistein inhibited parasite-induced Met
phosphorylation genistein or DMSO was added to cultured
Huh7 cells and the cultures were inoculated with 3610
4 P. berghei
ANKA sporozoites. Four hours later total protein extracts were
analysed with anti-phospho c-met (Tyr1234/1235) and MET
antibodies. As shown in Figure 6, sporozoite infection induced Met
phosphorylation and this was inhibited by genistein.
Discussion
Prophylaxis against malaria remains a major concern in regions
where the disease is endemic. Existing regimens for malaria
prophylaxis are suitable for short time travelers but not for
populations living in endemic areas. An alternative to most current
strategies to combat malaria is to target and modulate host
components known to be involved in the establishment of infection
by the parasite. At first sight this approach appears to be
counterintuitive. Indeed, an important requirement of traditional
anti-microbial chemotherapy is not to interfere with functions of the
host. However, targeting of host discrete components that the
parasite seems to modulate has the advantage that drug resistance
cannot result from direct alterations of the drug target [12].
Quinolines andartemisininsareexceptional amongstanti-microbial
drugs in that they target heme, a component of the host [13].
Resistance to quinolines developed very slowly as it required the
selection of variants that affect drug transport. Resistance to
artemisinins has not yet developed in the field, although some
studies indicate that the parasite may acquire resistance to this drug
[12,14]. Resistance is even less likely to occur if the targeted host
component remains outside the pathogen [15].
In the present study, we show that the tyrosine kinase inhibitor
genistein inhibits sporozoite development, in the liver in vitro as well as
in vivo. The reduction of liver infection results in a reduction of the
parasite load in the subsequent blood stage of the infection.
Decreasing the parasite load in the liver has been shown to reduce
the severity of the disease in the subsequent blood stage of the
infection [2,3]. Here, we show that genistein reduces the risk of
development of severe disease during the later blood stages by
reducing the parasite load in the liver. Our data shows that, in the
amount included in the supplemented diet, genistein does not affect
blood parasitemia directly, which does not imply that, at higher
concentrations, genistein does not have a direct effect on malaria
blood stages, as in fact previously shown in vitro [6–8]. If the results
described here, using malaria mouse models, can be reproduced in
humans, genistein has the potential to decrease malaria morbidity
and mortality in endemic areas. Epidemiological studies show that
after the initial period in which children are susceptible to severe
malaria, there is a sequential development of three types of protective
immunity: first, immunity that reduces the incidence of life-
threatening disease; second, immunity that reduces the incidence of
s y m p t o m a t i ci n f e c t i o n ;a n do n l yt h e n ,t h i r d ,i m m u n i t yt h a tr e d u c e s
parasitization [16]. Natural nonsterilizing immunity that develops in
people in sub-Saharan Africa occurs by constant exposure to the
parasites [17]. Thus, the fact that genistein does not totally block
infection might turn out to be an advantage of the strategy of
prophylaxisthat we envisage. In endemic areas,genisteinmayreduce
the incidence of severe malaria by decreasing liver infection and, at
the same time, allow the establishment of natural immunity.
Inourpreviousworkwehaveshownthatsporozoite-inducedMet
phosphorylation facilitated the development of the parasite in the
liver [9]. Here we show that the tyrosine kinase inhibitor genistein
inhibits sporozoite induced Met phosphorylation. It is conceivable
that this inhibition of Met activation is at least partly responsible for
the inhibition of parasite development by genistein. However,
additional or even alternative mechanisms of action by genistein
cannot be excluded at the present time. Recent results from our
laboratory have implicated several other kinases, including at least
one tyrosine kinase, in the liver stage of Plasmodium infection
(Prude ˆncio et al., unpublished results). Thus, genistein may reduce
infection by inhibiting more than one tyrosine kinase. Genistein is
also known to inhibit a variety of other enzymes such as thyroid
peroxidases [18], and topoisomerases [19,20]. Moreover genistein
interacts with P1-purinergic (adenosine) receptor in thyroid cells
[21] as well as with several members of the nuclear receptor family
such as estrogen receptors and peroxisome proliferator activator
receptors (PPARs) [22–24]. Whether inhibition of infection by
genistein involves any of these and/or other proteins expressed by
hepatocytes is not yet known. In the present study we have not
observed an effect of genistein pretreatment of sporozoites on the
Figure 6. Effect of genistein on Plasmodium sporozoite-induced MET phoshorylation. Cultured Huh7 cells were treated with genistein or
DMSO (control), and inoculated with 3610
4 P. berghei ANKA sporozoites. Four hours later total protein extracts were analyzed with anti-phospho c-
met (Tyr1234/1235) and MET antibodies. Quantification of intensity of each band was performed and plotted on a graph.
doi:10.1371/journal.pone.0002732.g006
Prophylactic Strategy
PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2732infection rate. This finding suggests that genistein has no direct
effect on protein(s) expressed by sporozoites before infection, but
doesnot exclude an effect of genisteinon the parasite after infection.
Parasite-encoded tyrosine kinases are unlikely to be targets for the
action of genistein, since the recent annotation of genomes from
several Plasmodium species have not identified genes coding for
molecules clustering for the tyrosine kinase (TK) group [25].
However, one might speculate that the inhibitionof topoisomerase I
and II, by genistein, reduced the replication rate of the parasite.
While this possibility cannot be excluded, it is unlikely that the
treatment used in our study resulted in the high genistein levels in
hepatocytes that are required to inhibit topoisomerases [19,20,26–
28]. In addition, the fact that Plasmodium blood stages are not
affected by the same amounts of genistein (Figure 4D) suggests that,
in the concentrations and conditions used, a direct effectof this drug
on the parasite is quite unlikely.
The diet of many people in the world, in particular in Japan, is
enriched in genistein. Soy beans are a major source of genistein.
Because of its putative health benefits (inhibition of osteoporosis,
anti-cancer effects, anti-inflammatory effects) genistein is widely
available in developed countries as a food supplement. If genistein
is to be used for malaria prophylaxis, its safety in neonates, young
children and pregnant women is mandatory. The safety of
genistein supplementation, and in particular of soy-based infant
formulae, has been reviewed in the UK by an expert committee
and by an expert pannel of the National Toxicology Program in
the USA (http://www.food.gov.uk/science/ouradvisors/toxicity/
COTwg/wg_phyt., http://cerhr.niehs.nih.gov/chemicals/genistein-
soy/genistein/genistein-eval.html and [29]). Both reports consider
soy-based infant formula safe, although both highlight the fact that
genistein accounts for only a small percentage of the total of the
isoflavones present in soy formulae. While the committee has not
found any clear evidence for adverseeffects of soy-rich diets in infants
and adults, it did emphasize the need for further research on the
potential, adverse effects of soy-based infant formulae. Several recent
studies have addressed the safety of genistein supplementation in
adults. No obvious adverse effects were observed after daily ingestion
of up to 54 mg of genistein [30]. Although in the gavage and i.p.
distribution of genistein to mice doses of genistein higher than
54 mg/Kg/day per mouse were used, in our in vivo experiments with
the genistein supplemented diet genistein amounts in sera were never
higher than 5 mM (Table 1), which have been recently considered
non-toxic values of total genistein [31].
Moreover, genistein is inexpensive, easy to preserve and to
distribute. One approach to ensure distribution to a large number
of people would be to add the compound to flour, a dietary staple
in many malaria endemic countries. Alternatively one might
envisage including soy plants in agriculture and soy beans in the
diet of populations in endemic countries, as has recently been
suggested as a strategy to improve both the health and the
economy of these populations (http://www.idrc.ca/en/ev-31644-
201-1-DO_TOPIC.html). Since genistein is safe and widely
consumed as a natural constituent or a supplement in diets of
Western populations, testing its potential for malaria prophylaxis
in non-human primate models of malaria might be envisaged as an
intermediate step towards determining whether the protective
effects we have observed in mice can be confirmed in humans.
Materials and Methods
Cells and parasites
HepG2, and Hepa1-6 cells (human and mouse hepatoma cell
lines, respectively) were maintained in DMEM 10% FCS, 1%
Penicillin/Streptomycin and 1 mM glutamine. HepG2 or Hepa1-
6 cells (2610
5) were seeded in 24-well plates and allowed to adhere
for 24 hours before infection. Huh7 cells (human hepatoma cell
line) were maintained in RPMI 10% FCS, 1% Penicillin/
Streptomycin and 1 mM glutamine. Huh7 cells (1,75610
5) were
Table 1. Genistein concentration in mouse sera (*p,0,05;
***p,0,001)
Genistein
Admnistration
(oral)
Time of
measurement
Genistein
Concentration
(mM)
Genistein
Concentration
(ng/ml)
Single dose
Control (H2O)
6 h after gavage 0,42 114,0
0,06 17,4
Single dose
(200 mg/kg)
2 h after gavage* 7,07 1910,6
15,00 4053,2
13,25 3581,5
7,23 1952,7
6 h after gavage 2,29 619,9
0,57 153,8
0,32 87,7
0,45 124,2
Control Diet 7–9 weeks old mice 0,11 32,0
0,09 26,4
0,19 52,2
0,21 55,6
0,19 51,3
0,47 126,9
0,39 104,6
0,15 41,5
0,14 37,5
0,13 36,3
0,28 75,2
0,13 36,3
0,13 35,5
0,17 46,9
Genistei
Supplemented-diet
(1000 ppm)***
7–9 weeks old mice 3,32 896,6
1,99 539,1
1,35 367,0
2,26 611,5
3,02 818,0
1,34 362,7
3,14 848,5
3,75 1013,9
0,20 55,0
1,11 300,9
0,84 227,9
1,37 371,1
0,68 184,8
1,16 313,8
1,16 313,9
1,42 385,9
doi:10.1371/journal.pone.0002732.t001
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infection. Green fluorescent protein (GFP)-expressing P. berghei
ANKA sporozoites [32] were obtained from the dissection of
infected Anopheles stephensi mosquito salivary glands.
In vitro infection
P. berghei ANKA sporozoites (4610
4/well) were added to
monolayers of Hepa1-6 or HepG2 cells in 24-well plates. At the
time of infection (t0) a range of genistein doses were added to the
medium. As control, an equivalent volume of DMSO (dimethyl-
sulphoxide) was added. After 24 hours cells were fixed and stained
with mouse anti-EEF (exo-erythrocytic forms of the parasite)
antibody (2E6) [33], followed by an anti-mouse secondary
antibody. In all experiments, genistein was left in the cultures
since the time of addition until the cells were fixed for
quantification of infection. Infection was quantified by counting
the total number of EEFs per coverslip using fluorescence
microscopy (magnification 4006). To assess the time window at
which genistein has an effect on infection, P. berghei ANKA
sporozoites (4610
4/well) were added to the monolayers of HepG2
cells and genistein was added at different time-points. Pre-
treatment of cells was performed by adding genistein to cells for
2 hours followed by wash and addition of sporozoites. The level of
infection was measured as described above, 24 hours post-
infection with sporozoites. Quantification of the area of 100
individual EEFs of each group was performed using ImageJ 1.36b
software. The results are expressed as areas in mm
2.
Viability of genistein-treated cells and sporozoites
HepG2 cells (2610
5) were seeded in 24-well plates and allowed
to adhere for 24 hours before addition of genistein at doses of
25 mM or 250 mM. Twenty four hours later the number of
adherent cells was determined in 10 fields per coverslip, in
triplicates. The number of adherent cells was also observed
48 hours post genistein treatment. To test whether genistein had a
direct effect on the parasite, sporozoites were treated for
30 minutes with 100mM genistein. Control sporozoites were
treated with equivalent volume of DMSO. After 30 min of
incubation, sporozoites were washed and added to a monolayer of
HepG2 cells seeded 24 hours before. Infection was assessed
24 hours later by determining the number of EEFs in each well.
Additionally cells were allowed to grow both in the presence of
genistein and taxol, a microtubule depolimirizing drugs that causes
cell dead, and 24 hours later percentage of cell death was
determined by flow cytometry with propidium iodide staining,
Fluorescence Activated Cell Sorting (FACS) analysis
FACS analysis at 2, 6, 30 and 44 hours after sporozoite addition
was performed to determine the percentage of parasite-containing
cells and parasite-GFP intensity within infected cells. Cell samples
for FACS analysis were processed as previously described [10].
Mice and genistein administration
C57BL/6 mice were bred and housed in the pathogen-free
facilities of the Instituto de Gulbenkian de Cie ˆncia following all the
EU regulations. The mice were then moved to the Instituto de
Medicina Molecular Animal House were all the experiments were
performed. All protocols were approved by the IMM Animal Care
Committee. Seven to 10 week old male and female C57Bl/6 mice
were treated with genistein or vehicle (control), and infected with
P. berghei ANKA sporozoites. For intraperitoneal administration,
mice were treated with a single dose of genistein (200 mg/kg in
200 mL DMSO) or DMSO alone (controls), immediately before P.
berghei ANKA sporozoite inoculation. For oral administration, a
suspension of genistein in water (200 mL, 200 mg/kg) was given to
mice by gavage 6 hours prior to infection with 1610
4 P. berghei
ANKA sporozoites. For genistein administration in the diet, mice
were given food supplemented with one thousand parts per million
(1000 ppm) genistein (genistein 1000 ppm RM3(P)–SDS, Eng-
land). Control mice were fed with the same diet without genistein
supplementation (RM3(P)–SDS, England). Mice were fed starting
on their weaning date, and for at least 5 weeks before infection
with sporozoites, or breeding couples and their litters were kept on
genistein supplemented or control diet through generations. All
mice were infected with 1610
4 P. berghei ANKA sporozoites
between the ages of 7 and 9 weeks old and liver infection was
determined 40 hours later. In a parallel set of experiments,
sporozoite infection was allowed to proceed to blood stage, to
assess the impact of genistein in disease progression.
Quantification of liver infection by quantitative Real Time
PCR
Mice treated with genistein and controls were infected by
intravenous injection with 1610
4 P. berghei ANKA sporozoites.
Forty hours post-sporozoite injection, livers were dissected and
homogenized, and total RNA was extracted with an RNeasy Mini
kit Quiagen, according to the manufacturer’s recommendation.
cDNA was obtained by reverse transcription using the First-strand
cDNA synthesis kit (Roche) following the manufacturer’s instruc-
tions. Quantitative RT-PCR reactions were performed for
quantification of parasite load, using an ABI PRISM 7000,
Applied Biosystem, and specific primers for Plasmodium berghei 18 S
rRNA (59-AAGCATTAAATAAAGC GAATACATCCTTAC-39
and 59-GGAGATTGGTTTTGACGTTTATGTG-39); or specif-
ic primers for P. yoelii 18 S rRNA (59 –GGGGATTGGTTTT-
GACGTTTTTGCG-39 and 59-AAGCATTAAATAAAGCGAA-
TACATCCTTAT-39) were used for quantification of parasite
load in the livers of mice 40 hours after sporozoite challenge [34].
The amplification program consisted of incubation at 50uC for
2 min, 95uC for 10 min, followed by 50 cycles at 95uC for 15 s
and 60uC for 1 min. For external standardization, plasmids
encoding cDNA fragments cloned into TOPO TA, Invitrogen;
corresponding to the amplified regions of the corresponding genes,
were utilized. Copy numbers were calculated comparing the cycle
numbers of the log-linear phase of the samples with the cycle
numbers of the external standards.
Genistein quantification in the sera
‘‘Free’’ analytes_aglycones, were extracted from the plasma/
serum sample with ethyl acetate. The organic phase was
evaporated and the dried residue was reconstituted in the mobile
phase. For determination of the ‘‘total’’ isoflavones the glucuro-
nide- and sulphate-conjugates were cleaved by enzymatic
hydrolysis prior to ethyl acetate extraction. Chromatographic
separation was performed by HPLC/MS on a C18-column in the
gradient mode. Mass spectrometric detection (Agilent LC/MSD
VL single-quadrupole-mass spectrometer equipped with elektros-
pray-ion source) was carried out with negative electrospray
ionisation in the SIM-mode. Specifically, 200 ml of plasma were
transferred into a 2 mL Eppendorf tube and 100 ml of enzyme
solution were added. For enzymatic cleavage of the glucuronide-
and sulphate-conjugates the samples were incubated at 38uC for
3 h, followed by addition of 30 ml internal standard solution. For
extraction, 1200 ml ethyl acetate was added to the sample, shaken
for 5 min at 300 rpm and centrifuged for 10 min at 10000 rpm
and 10uC. 1000 ml of the supernatant was transferred into a 2 ml
Eppendorf tube and evaporated at 30–35uC to dryness with a
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reconstituted in 150 ml mobile phase, briefly vortexed, and
transferred into an HPLC vial. Forty to 75 ml were injected onto
the analytical column and analyzed by HPLC-MS [35]. Data
acquisition of extracted ion chromatograms, integration and
quantification was performed with the Chemstation Software
(Version 9.03 or higher) from Agilent Technologies.
Quantification of blood infection and severity of disease
After sporozoite inoculation, peripheral blood parasitemias were
followed daily by counting parasites in Giemsa stained thin blood
films. To accurately quantify parasitemia in the first 96 hours post-
infection, 50 to 100 microscope fields were examined in each
blood film. At later time points, when the levels of parasitemia
were higher, 20 microscope fields were counted per mouse. Mice
were checked daily for development of ECM symptoms, which
include ataxia, paralysis, deviation of the head and convulsions,
coma and death.
Blood stage infection
Mice fed on a 1000 ppm genistein supplemented diet or control
diet were infected with 1610
6 P. berghei ANKA iRBC that were
freshly obtained after one passage from infection with a frozen vial.
Peripheral blood parasitemia and ECM symptoms were deter-
mined as described above.
Whole-cell lysate preparation
To detect the human hepatocyte growth factor receptor (h-
MET) and determine its phosphorylation state, total cell extracts
were prepared by suspending cell pellets in cold buffer A (20 mM
Tris-HCl, pH 7,5; 1% (v/v) NP40; 13,7 mM NaCl; 0,5 mM
EDTA; 15% (v/v) glicerol; 1 mM DTT) suplemented with
protease and phosphatase inhibitors, for 30 min on ice followed
by centrifugation at 14000 rpm, for 15 min at 4uC. Protein
concentrations were determined using the Bio-Rad Laboratories
DC protein assay kit and equal amounts of protein extracts
(40 mg) were separated by 8% SDS-PAGE gels, transferred onto
nitrocellulose membranes and processed for Western blotting. The
antibody directed to phospho-MET was used at 1:1000 dilution
(#3126; Cell signalling technology, Inc.) and b-chain of human
MET was detected with the antibody MET (C-12) at 0,5 mg/mL
dilution (#sc-10; Santa Cruz Biotechnology, Inc.). After incuba-
tion with the primary antibodies the enhanced chemiluminescence
detection system ECL and Kodak films (Amersham Pharmacia
Biotech, Piscataway, NJ) were used to visualize proteins on the
nitrocellulose blots.
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